EGFR and neoplasm: PAI, which reports the “binding potential” (BP, a value proportional to receptor concentration), has been used in a variety of EGFR-overexpressing xenograft cell lines to demonstrate that tumor-averaged binding potential scales linearly with EGFR both in vivo and ex vivo [13].